Related Experiment Video
Updated: May 28, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Systemic Immune-Inflammation Index and Systemic Inflammation Response Index in Psoriasis: Limited Utility for
Federico Bardazzi1, Alessio Natale1,2, Lorenzo Maltoni3
1Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Dermatology Practical & Conceptual
|May 26, 2026
Summary
Systemic Immune Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) did not reliably track disease activity in psoriasis patients treated with IL-23 inhibitors. These inflammatory markers showed variable behavior, limiting their use for monitoring treatment response.
Area of Science:
- Dermatology
- Immunology
- Biomarker Research
Background:
- Psoriasis is a chronic inflammatory skin condition linked to systemic inflammation.
- Systemic Immune Inflammation Index (SII) and Systemic Inflammation Response Index (SIRI) are emerging blood-based biomarkers for inflammation.
- Their utility in monitoring psoriasis during biologic therapy, especially IL-23 inhibitors, requires further investigation.
Purpose of the Study:
- To assess the effectiveness of SII and SIRI in monitoring disease activity in severe psoriasis patients undergoing treatment with IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab).
Main Methods:
- A retrospective observational study involving 120 patients with moderate-to-severe psoriasis.
- Assessment of SII, SIRI, and Psoriasis Area and Severity Index (PASI) at baseline, 6 months, and 12 months.
- Analysis of correlations between inflammatory indices and comorbidities like obesity, diabetes, and hypertension.
Main Results:
- Despite significant PASI improvements, SII and SIRI levels fluctuated inconsistently and did not correlate with clinical response to IL-23 inhibitors.
- No clear trends in SII or SIRI were observed across guselkumab, risankizumab, or tildrakizumab treatment groups.
- Weak to moderate correlations were found between SII/SIRI and comorbidities.
Conclusions:
- SII and SIRI are not reliable indicators of treatment response in psoriasis patients on IL-23 inhibitors.
- The variability and association with comorbidities limit their value as specific biomarkers for psoriasis.
- Development of more targeted systemic inflammation markers is necessary for this patient population.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...